GoldenGolden
Advanced Search
Solid Biosciences

Solid Biosciences

Solid Biosciences is a Cambridge, Massachusetts-based biotechnology company focused on solving Duchenne muscular dystrophy.

Solid Biosciences is a life sciences and biotechnology company focused on solving Duchenne muscular dystrophy. The company utilizes expertise in science, technology, disease management, and care in order to research and develop therapies for attacking the roots of the disease and improving quality of life of patients.

Timeline

July 2, 2021
Solid Biosciences announces the grant of an inducement award to its newly appointed Senior Vice President, Clinical Development, Roxana Dreghici.
March 2021
Solid Biosciences raises a $143,800,000 venture round.
December 11, 2020
Solid Biosciences raises a $90,000,000 venture round from Aspire Capital Fund, Bain Capital Life Sciences, Boxer Capital, EcoR1 Capital, Ikarian Capital Llc, Perceptive Advisors, RA Capital Management and Suvretta Capital Management.
October 23, 2020
Solid Biosciences raises a $40,000,000 venture round from Ultragenyx Pharmaceutical.
March 30, 2017
Solid Biosciences raises a $50,000,000 series C round from Bain Capital Life Sciences, Biogen, Cormorant Asset Management, Foresite Capital, Janus Capital Group, Leerink Partners, Perceptive Advisors, RA Capital Management and RTW Investments LLC.
November 3, 2015
Solid Biosciences raises a $42,500,000 series B round from Perceptive Advisors.
2013
Solid Biosciences was founded by Andrey Zarur, Annie Ganot, Ilan Ganot and Matt Arnold.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
June 15, 2021
BioSpace
Senda Biosciences, Inc. today announced the appointments of Matthew Osborne , as Chief Financial Officer, Lynette Herscha , as Chief Legal Officer, and Rajesh Beri , Ph.D., as Vice President of Process Development.
BioSpace
June 7, 2021
BioSpace
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Dr. Iman Barilero has joined the Company as Chief Regulatory Officer, effective Dr. Barilero brings three decades of experience as a strategic executive in the healthcare industry, successfully designing innovative and integrated regulatory pathways that gaine

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.